As of Sep 23
| +0.24 / +0.47%|
The 24 analysts offering 12-month price forecasts for Teva Pharmaceutical have a median target of 65.50, with a high estimate of 100.00 and a low estimate of 57.00. The median estimate represents a +27.26% increase from the last price of 51.47.
The current consensus among 28 polled investment analysts is to Buy stock in Teva Pharmaceutical. This rating has held steady since September, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.